News

Tirzepatide and Gallbladder Risk: Small but Real

Creator: Nadia Okonjo, Health Writer
Published: 2026-09-12

Gallstones turn up in about 1 in 100 people on tirzepatide in the trials — barely above placebo — but inflamed gallbladders are three and a half times as common. Here is why, and the pain pattern that means call someone today.

Nadia Okonjo, Health Writer September 12, 2026 7 min read

A woman sits on the wooden edge of a raised garden bed holding a small pot of seedlings

The short version

In the two weight-loss trials behind the brand-name tirzepatide, gallstones were reported in 1.1% of people on the drug and 1.0% on placebo. The gap sits in the more serious events: gallbladder inflammation 0.7% against 0.2%, and gallbladder removal 0.2% against none.
Two forces push the same way. Tirzepatide slows how the gallbladder empties, and losing weight quickly makes bile more likely to form stones — in an eight-week study of a strict low-calorie diet, 13 of 51 dieters formed new gallstones and none of the 26 non-dieters did.
Across 76 randomised trials and 103,371 people, GLP-1 medicines raised gallbladder and biliary disease by about a third (relative risk 1.37), with a larger increase in weight-loss trials, at higher doses, and with longer treatment.
A pooled analysis of the semaglutide weight-loss trials published in July 2026 found about 2.0 gallbladder events per 100 patient-years on the drug against 0.8 on placebo — roughly double a small number, and the authors note trials miss the stones nobody feels.
Steady pain under the right ribs lasting more than five or six hours, especially with fever, repeated vomiting or yellowing of the eyes, is the pattern that gets a same-day call.

Yes, there's a real link between tirzepatide and gallbladder trouble — and no, the drug isn't doing all of it. In the two weight-loss trials behind the brand-name product, gallstones were reported in about 1 in 100 people taking tirzepatide and about 1 in 100 taking placebo: 1.1% against 1.0%, essentially the same. The gap opens further along, at the events that actually hurt. An inflamed gallbladder was reported in 0.7% of people on tirzepatide and 0.2% on placebo, and 0.2% had the gallbladder removed, against nobody on placebo.

Small numbers. Not nothing, either — and why they move at all is the useful part, because it tells you what to watch for.

How often tirzepatide and gallbladder problems actually happen

Those figures come from the current label for Zepbound, the brand-name tirzepatide sold for weight management, revised in August 2026, pooling two trials in 2,519 adults treated for up to 72 weeks. The label adds one line that does a lot of work: the gallbladder events were associated with weight reduction.

Widen the lens and the picture holds. A review of 76 randomised trials covering 103,371 people found GLP-1 medicines raised the risk of gallbladder or biliary disease by about a third — a relative risk of 1.37 (He et al., JAMA Internal Medicine 2022). In the weight-loss trials it more than doubled, and it rose with higher doses and longer treatment.

Which is the whole story in one sentence: the more weight you lose, and the faster you lose it, the more this matters.

Why it happens: two things at once

The first is mechanical. The gallbladder is a small bag under the liver that stores bile and squeezes it out when a meal arrives. GLP-1 medicines slow that squeeze and stretch out the refilling phase, so bile sits still for longer — and still bile can settle into stones. A 2019 review of how gallbladder emptying is controlled concluded that this longer refilling may explain the events seen in GLP-1 trials (Gether, Nexøe-Larsen and Knop, Journal of Clinical Endocrinology & Metabolism 2019).

The second has nothing to do with any medicine. Losing weight fast, by any route, changes what bile is made of: the liver pushes more cholesterol into it, and cholesterol is what most gallstones are. The clearest demonstration is old and blunt. Fifty-one adults with obesity went on a strict low-calorie diet and had gallbladder ultrasounds every four weeks. By week eight, 13 of them — a quarter — had new gallstones. Of the 26 who did not diet, none did (Liddle, Goldstein and Saxton, Archives of Internal Medicine 1989).

Surgeons plan around the same physiology after bariatric surgery, where fast weight loss is the point. Tirzepatide lands in similar territory — average reductions of 15.0% at 5 mg and 20.9% at 15 mg over 72 weeks in SURMOUNT-1, a trial of 2,539 adults — and inherits the same side of the bargain, as tirzepatide weight loss results show.

What the newest numbers add

As of September 6, 2026, the day this article was written, the two freshest studies are both about the drug class rather than tirzepatide alone. Tirzepatide-specific meta-analyses have pooled gallbladder and biliary events from randomized trials (Zeng et al., Frontiers in Endocrinology 2023; Gong et al., Journal of Diabetes Investigation 2025).

A pooled analysis of the semaglutide weight-loss trials, published in July 2026, counted events across four placebo-controlled trials and 3,683 participants: about 2.0 per 100 patient-years on semaglutide against 0.8 on placebo, a risk ratio of 2.08 (Ukkonen et al., Diabetes, Obesity and Metabolism 2026). Roughly double a small number.

The same paper makes a point most coverage skips. Trials only count gallstones somebody complained about, and most gallstones never cause a symptom. So more people probably form stones than the trial numbers show; what those numbers describe is how many ran into trouble.

A real-world study published in June 2026 followed 39,140 matched pairs of adults with type 2 diabetes for three years. GLP-1 use came with more gallstones (adjusted odds ratio 1.43), more gallbladder inflammation (1.45) and more removals (1.54) (Eldesouki et al., United European Gastroenterology Journal 2026) — same direction, same modest size, in ordinary practice rather than a trial.

The pain pattern that matters

Most gallstones sit quietly for years. When one does cause trouble it has a shape you can recognise, and it is nothing like the vague queasiness of the first few weeks on a GLP-1.

Gallbladder pain sits in the upper right of the abdomen, just under the ribs, and can travel round to the right shoulder blade. It is steady rather than crampy — it builds, holds, then eases. It often starts after a fatty meal, and often at night. An attack that fades within an hour or two is usually a stone that moved, and still earns a phone call the next morning.

What changes the urgency: pain that keeps going past five or six hours, fever or chills, vomiting that won't stop, yellowing of the eyes or skin, dark urine with pale stools. Those point to an inflamed gallbladder or a stone stuck in a duct — both same-day problems.

One caution: upper abdominal pain on a GLP-1 isn't always the gallbladder. Severe pain that bores through to the back is the pattern of pancreatitis, a separate labelled warning that needs its own assessment. The side effects of tirzepatide has the fuller list of what to flag and when.

Who has more to think about here

None of this lands evenly. What raises the odds:

Already having gallstones, including quiet ones found by accident on an old scan. Existing stones are the strongest predictor of symptomatic ones later.
Losing a lot of weight quickly. Both the trial data and the diet study point at speed and size of loss, not the calendar.
Higher doses and longer treatment, which is what the class review found — the dose ladder explains why most people spend months climbing it.
A previous episode of gallbladder inflammation, which shifts the conversation before the first prescription rather than after.

If your gallbladder has already come out, gallbladder stones are off the table. Stones can still form in the bile ducts, which is uncommon, and a provider will still ask about the surgery, because it changes what upper abdominal pain would mean.

Does semaglutide look any different?

Not meaningfully, on the evidence anyone has. There's no head-to-head trial with gallbladder events as an outcome, so anybody ranking the two on this is guessing. The class review found the effect across GLP-1 medicines generally, and the mechanism belongs to both.

The risk tracks the weight loss more than the molecule: someone losing a fifth of their body weight has more of it ahead of them than someone losing a twelfth, whichever medicine got them there. Semaglutide's side effects differ from tirzepatide's in ways that usually matter more day to day.

What a provider does with this

Gallbladder history is a standard question on the intake, and it isn't a box-tick. A licensed provider reviews every request and decides whether to prescribe, and not everyone qualifies. A prior gallbladder problem doesn't rule tirzepatide out on its own; it usually means a longer conversation about what happened, when, and whether the gallbladder is still there.

If stones show up during treatment, whether to continue, pause or send you for imaging belongs to the prescriber who knows the case. The label asks clinicians to order gallbladder studies when inflammation is suspected — it does not tell them to stop the medicine, and that call stays between a patient and their doctor.

Through Promise, tirzepatide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. Compounded medicines are not reviewed by the agency for safety, effectiveness or quality. None of the gallbladder biology changes with the source of the vial — what changes is whether somebody licensed looked at your history first.

Common questions

Does tirzepatide cause gallstones?

It nudges the odds up, and fast weight loss does more of the work than the drug does. In the pooled weight-loss trials behind the brand, gallstones were reported in 1.1% of people on tirzepatide and 1.0% on placebo, while gallbladder inflammation was 0.7% against 0.2%. Across 76 GLP-1 trials and 103,371 people, the class raised gallbladder and biliary disease by a relative risk of 1.37.

What does gallbladder pain feel like on tirzepatide?

Steady pain in the upper right of the abdomen, under the ribs, often after a fatty meal and often at night. It can travel to the right shoulder blade, and it builds and holds rather than cramping. An attack running past five or six hours, or one that comes with fever, repeated vomiting or yellowing of the eyes, is a same-day problem rather than something to sit on.

Can you take tirzepatide if your gallbladder has been removed?

Often yes, and it is a question for the prescriber rather than a rule. With no gallbladder there is nowhere for gallbladder stones to form, so that particular risk is gone. Stones can still form in the bile ducts, which is uncommon, and the surgery changes what upper abdominal pain would mean, so a provider will ask when and why it happened.

Should you stop tirzepatide if you get gallstones?

That is the prescriber's call, and it turns on whether the stones are causing symptoms. The prescribing information asks clinicians to order gallbladder studies when inflammation is suspected; it does not direct them to stop the medicine automatically. Plenty of people with quiet stones carry on under monitoring. Anyone having an active attack needs assessment first, and the decision sits with the patient and their doctor.

Is compounded tirzepatide FDA-approved?

No. FDA-approved versions of tirzepatide exist — Zepbound and Mounjaro — but the compounded formulation offered here is not FDA-approved. A compounded medicine is prepared by a licensed U.S. pharmacy for one patient on a prescription, and it is not reviewed by the agency for safety, effectiveness or quality. A licensed provider still decides whether to prescribe it.

Does everyone on tirzepatide need a gallbladder scan?

No routine scan is standard. Ultrasound is used when symptoms point at a problem, not as screening for everyone starting treatment. The label directs clinicians to order gallbladder studies when inflammation is suspected. A provider may take a different view for someone with a history of stones or a previous attack, which is one reason that history goes on the intake.